. . "Putative L-asparaginase precursor"@en . " "@en . "For treatment of acute lympocytic leukemia and non-Hodgkins lymphoma"@en . . . . . "L-asparagine amidohydrolase from E. coli"@en . . . . . . . . "9015-68-3"@en . "# Appel IM, van Kessel-Bakvis C, Stigter R, Pieters R: Influence of two different regimens of concomitant treatment with asparaginase and dexamethasone on hemostasis in childhood acute lymphoblastic leukemia. Leukemia. 2007 Jun 7;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17554375 # http://www.google.com/patents/EP2046369A2"@en . "L-asparagine amidohydrolase"@en . . "Humans and other mammals"@en . . "Asparaginase"@en . "8-30 hrs"@en . "Masao Nambu, \"Process for producing immobilized L-asparaginase preparations for the therapy of leukemia.\" U.S. Patent US4617271, issued January, 1977."@en . . . . . "Asparaginase converts asparagine to aspartic acid and ammonia. It facilitates production of oxaloacetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and so the loss of exogenous sources of asparagine leads to cell death."@en . . "approved"@en . . .